Feature | June 16, 2014

SCAI Publishes Expert Recommendations for Most Common Form of Peripheral Artery Disease

Second in appropriate use series provides guidance on treatment for blocked arteries above the knee

June 16, 2014 — New appropriate use expert consensus documents developed by the Society for Cardiovascular Angiography and Interventions (SCAI) provide guidance on treating the most common form of peripheral artery disease (PAD), namely blockages that affect arteries above the knee. The paper e-published in Catheterization & Cardiovascular Interventions is the second in a series of PAD treatment recommendations released by SCAI. The series is aimed at helping physicians determine treatment options for the growing number of patients impacted by PAD.

The newly published criteria address PAD in the femoropopliteal (FP) segment, the most common location of the disease. While most people with FP disease are asymptomatic, some patients whose severe blockages markedly reduced blood flow experience impaired walking, a condition known as intermittent claudication. Patients with more extensive blockages may develop critical limb ischemia in which the limb is threatened and may need amputation. These patients classically have blockages both above and below the knee. Patients with long-standing diabetes and/or chronic kidney disease and the elderly are most at risk of developing such blockages. As the population ages and number of patients with diabetes rises, the rate of critical limb ischemia is expected to grow.

“Our goal in treating patients with femoropopliteal disease is to reduce pain, improve walking ability and enhance quality of life,” said Douglas E. Drachman, M.D., FSCAI, director of the Cardiology Fellowship Program at Massachusetts General Hospital and senior author of the consensus paper. “As technology has advanced, there are now safe and effective endovascular treatment options for a range of patients, not just those at high surgical risk.”

An expert panel developed the new recommendations by reviewing scientific data available on each treatment option. The panel found that balloon angioplasty continues to be a valid treatment, but with suboptimal long-term results in patients with long blockages, critical limb ischemia, diabetes or areas of complete blockage. The paper discusses use of self-expanding stents, covered stents and non-stenting alternatives, including atherectomy, in which obstruction is relieved by extracting arterial plaque.

The expert consensus document is the second in SCAI’s series of appropriate use recommendations for treating PAD. The earlier document, “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Aorto-Iliac Arterial Intervention,” was published in May 2014.  Forthcoming publications, addressing infrapopliteal PAD and renal artery stenosis, will be published in Catheterization & Cardiovascular Interventions later this summer.

“As the incidence of PAD grows, SCAI is committed to helping physicians provide the best treatment options for the patient’s own condition and treatment goals,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “We want to help physicians find the safest treatment option that provides the greatest relief and improves quality of life.”

The paper, titled “Appropriate Use Criteria: A Society for Cardiovascular Angiography and Interventions (SCAI) Consensus Statement for Femoral-Popliteal Arterial Intervention,” is published in Catheterization & Cardiovascular Interventions.

For more information: www.scai.org

Related Content

Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
medicare bundled cardiac payments, CMS cardiology payments
Feature | Business| October 24, 2016 | By John W. Meyer, MPH, FACHE
(Editor’s note: This is the second part of a two-part series on the proposed Medicare five-year demonstration for
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
3-D bioprinting, 3-D printing, printed organs, 3D bioprinting

3-D printed vessel made from living cells implanted in an animal to test feasibility of using such structures clinically. Blood vessels are a stepping stone to the creation of more complex 3-D printed organs made from biomaterials. Image from the South Carolina Project for Organ Biofabrication.


Feature | 3-D Printing| October 13, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) changed its rules concerning custom medical devices Oct.
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
Overlay Init